FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 2005

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Zauderer Maurice						2. Issuer Name and Ticker or Trading Symbol VACCINEX, INC. [VCNX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title Other (specify)					
(Last) C/O VAO 1895 MO		Date of 1/23/20		st Tra	insactio	on (Mo	nth/Day/Year)		X Office below)	lent and	belo		ecily					
1895 MOUNT HOPE AVENUE (Street) ROCHESTER NY 14620						If Amen	idment	t, Dat	e of Ori	iginal F	Filed (Month/Da		Individual or Joint/Group Filing (Check Applicable Line) Y Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S		(Zip)																
			le I -	Non-Deriv	_	2A. Deer			cquii	red, I	4. Securities A			5. Amount		6. Owne	ership	7. Nat	ture of
1. Title of Security (Instr. 3)				Date (Month/Day/\)	(ear)	Executi if any	xecution Date,		Transaction Code (Instr. 8)		Disposed Of (D) (Instr. 3, 4 and		4 and 5)	Securities Beneficial Owned Fo Reported Transactio	ly llowing	Form: D (D) or In (I) (Instr	irect direct : 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common	Stock								Code	V	Amount	(D)	Price	(Instr. 3 ar		D	,		
Common Stock Common Stock														213,2		I		By Jeres C. Zaud Trust ⁽¹⁾	
Common Stock														212,1	212,161		I M		ordan derer t ⁽¹⁾
Common Stock			11/23/2022					A		1,511,430(2)	A	\$0.5293	4,410,984(2)		I		By Vaccinex (Rochester), L.L.C. ⁽²⁾		
																		L.L.\	<u>C.</u>
		1	able								sposed of,			y Owned				D.D.	C
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. I Exec if an	(e.g., p Deemed cution Date,	outs, 4. Trans			rrani imber rative rrities ired r osed) r. 3, 4	6. Da	otion	cisable and	7. Title ar of Securit Underlyir	urities) ad Amount ties ag e Security		derivat Securi Benefi Owned Follow Report	tive ities icially d ving ted action(s)	10. Owners Form: Direct (or Indir (l) (Instr	ship D)	11. Nature of Indirect Beneficial Ownershi (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	3. Transaction Date	3A. I Exec if an	(e.g., posemed cution Date,	4. Trans Code	, calls	5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr	rrani imber rative rrities ired r osed) r. 3, 4	6. Da Expir (Mon	te Exer	es, converti	7. Title ar of Securi Underlyir Derivative	urities) ad Amount ties ag e Security	8. Price of Derivative Security (Instr. 5)	derivate Securi Benefi Owned Follow Report Transa	tive ities icially d ving ted action(s)	10. Owners Form: Direct (ship D)	11. Nature of Indirect Beneficial Ownershi
Derivative Security	Conversion or Exercise Price of Derivative	3. Transaction Date	3A. I Exec if an	(e.g., posemed cution Date,	4. Trans Code 8)	, calls	5. Nu of Deriv Secu Acqu (A) on Dispo of (D) (Instr and 5	rrans mber vative crities nired r osed) r. 3, 4	6. Da Expli (Mon	otion: te Exer ration I tth/Day	es, converti	7. Title ar of Securi Underlyir Derivativ (Instr. 3 a	urities) ad Amount ig g se Security nd 4) Amount or Number of	8. Price of Derivative Security (Instr. 5)	deriva Securi Benefi Ownec Follow Report Transa (Instr.	tive ities icially d ving ted action(s)	10. Owners Form: Direct (ship D)	11. Nature of Indirect Beneficial Ownershi
Derivative Security (Instr. 3) Stock Option (Right to	Conversion or Exercise Price of Derivative Security	3. Transaction Date	3A. I Exec if an	(e.g., posemed cution Date,	4. Trans Code 8)	, calls	5. Nu of Deriv Secu Acqu (A) on Dispo of (D) (Instr and 5	rrans mber vative crities nired r osed) r. 3, 4	6. Da Expir (Mon	otions te Exercision I tth/Day	expiration	7. Title ar of Securit Underlyin Derivative (Instr. 3 a	urities) ad Amount ties ag e Security and 4) Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)	derivat Securi Benefi Owned Follow Report Transa (Instr.	tive tites cicially d ving ted action(s) 4)	10. Owners Form: Direct or Indir (I) (Insti	ship D)	11. Nature of Indirect Beneficial Ownershi
Stock Option (Right to Buy) Stock Option (Right to Buy)	Conversion or Exercise Price of Derivative Security	3. Transaction Date	3A. I Exec if an	(e.g., p Deemed cution Date,	4. Trans Code 8)	, calls	5. Nu of Deriv Secu Acqu (A) on Dispo of (D) (Instr and 5	rrans mber vative crities nired r osed) r. 3, 4	Es, op 6. Da Expir (Mon	te Exercise to the Exercise to the Exercise It	Expiration Date	7. Title ar of Securi Underlyir Derivativ. (Instr. 3 a	urities) ad Amount ties ties tig e Security and 4) Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)	derivar Securi Benefi Owned Follow Report Transa (Instr	tive tities cially a ving ted action(s) 4)	10. Owners Form: Direct () or Indir (I) (Instr	ship D)	11. Nature of Indirect Beneficial Ownershi
Stock Option (Right to Buy) Stock Option (Right to Buy) Stock Option (Right to Buy)	Conversion or Exercise Price of Derivative Security	3. Transaction Date	3A. I Exec if an	(e.g., p Deemed cution Date,	4. Trans Code 8)	, calls	5. Nu of Deriv Secu Acqu (A) on Dispo of (D) (Instr and 5	rrans mber vative crities nired r osed) r. 3, 4	Date Exerc	tte Exertion I tth/Day	Expiration Date 03/31/2024	Title Common Stock Common	Amount or Number of Shares 2,589	8. Price of Derivative Security (Instr. 5)	derivar Securi Benefi Owned Follow Report Transa (Instr	tive titive tities cially of viring ted action(s) 4)	10. Owners Form: Direct (or Indir (I) (Instr	ship D)	11. Nature of Indirect Beneficial Ownershi
Stock Option (Right to Buy) Stock Option (Right to Buy) Stock Option (Right to Buy) Stock Option (Right to Buy)	Conversion or Exercise Price of Derivative Security \$14.9 \$7.1	3. Transaction Date	3A. I Exec if an	(e.g., p Deemed cution Date,	4. Trans Code 8)	, calls	5. Nu of Deriv Secu Acqu (A) on Dispo of (D) (Instr and 5	rrans mber vative crities nired r osed) r. 3, 4	Date Exert	te Exercise to Exe	Expiration Date 06/30/2024 12/23/2025	Title Common Stock Common Co	urities) ad Amount ities ig e Security and 4) Amount or Number of Shares 2,589 2,589	8. Price of Derivative Security (Instr. 5)	derivar Securi Benefi Ownec Follow Report Transa (Instr	tive tities cially a ving ted action(s) 4)	Direct (I) (Instr	ship D)	11. Nature of Indirect Beneficial Ownershi

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed Execution Date or Exercise (Month/Day/Year) if any				4. Transaction Code (Instr. 8)		vative rities rired rosed) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/\)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v			Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$1.29							(7)	04/01/2032	Common Stock	28,000		28,000	D	

Explanation of Responses

- 1. Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
- 2. Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- 3. Exercisable in full as of the date of this report.
- 4. This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date.
- 5. This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
- 6. This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.
- 7. This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date.

/s/ Scott E. Royer, Attorney-in-Fact for Maurice Zauderer 11/28/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.